Investigating lipid metabolites as markers for liver cancer
Official title: Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma
Run by Nanfang Hospital, Southern Medical University · NCT06623474 · Data updated 2026-11-12
This study is trying to see if certain fats in the blood can help doctors spot liver cancer earlier in patients with liver disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 900 (estimated) |
| Sponsor | Nanfang Hospital, Southern Medical University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | July 1, 2024 |
| Main results expected | June 30, 2032 |
| Study ends | July 1, 2032 |
| Registry record updated | October 9, 2024 |
| Trial ID | NCT06623474 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients aged 18-80 years who are undergoing hepatic resection for hepatocellular carcinoma.
✕Probably not a fit
Patients with advanced liver cancer involving major vascular structures or those with significant comorbidities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to analyze the correlation between lipid metabolites and hepatocellular carcinoma, a common malignant tumor in China. Researchers will conduct qualitative and quantitative analyses of various lipid metabolites found in the plasma and liver cancer tissues of patients undergoing hepatic resection. By collecting tumor-related pathological data, the study seeks to enhance early diagnosis and treatment strategies for liver cancer, particularly in patients with metabolic dysfunction-related liver disease.
Why it matters
Potential benefit: If successful, this study could lead to improved early diagnosis and treatment options for patients with hepatocellular carcinoma.
How similar studies have gone: Other studies have shown promising results in using lipid metabolites as biomarkers for various cancers, suggesting potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18-80 years old undergoing hepatic resection for hepatocellular carcinoma (diagnostic criteria for hepatocellular carcinoma refer to the guidelines for the diagnosis and treatment of primary hepatocellular carcinoma). * Voluntary signing of informed consent Exclusion Criteria: * In the judgment of the investigator, they are not suitable to participate in this study. * Patients with hepatic malignant tumors with invasion of the main portal vein and its first-order branches, the common hepatic duct and its first-order branches, the main hepatic vein and the inferior vena cava, or extrahepatic metastases. * Surgery with biliary tract exploration or reconstruction in the presence of biliary obstruction. * Surgery combined with splenectomy or splenic artery ligation * Preoperative combination of cardiac, pulmonary, renal and other organs with major underlying diseases.
Where it's running
-
Nanfang Hospital
Guangzhou, Guangdong, China Recruiting
Study contacts
- Study coordinator: Kai Wang, Doctor
- Email: kaiwang@smu.edu.cn
- Phone: 13710574386
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
InstaSure Non-Invasive Finger-Press Test for HCC
This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.
-
BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer
This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.
-
Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer
This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)
This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.
-
GLP-1 RA plus standard treatment in first-line metastatic GI cancers
This early-phase trial tests whether adding a GLP-1 receptor agonist to standard first-line chemotherapy is safe and feasible for people with metastatic pancreatic, colorectal, or liver cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.